Baheal’s 24% Take‑over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033
China‑based Baheal Pharmaceutical Group (SHE: 301015) announced a strategic cooperation agreement with Tianjin Jikun Pharmaceutical...
BMS Sells 60% Shanghai Stake to Hillhouse Capital, Shifting Focus to Growth
A leaked internal email from US major Bristol-Myers Squibb (BMS; NYSE: BMY) has recently surfaced...
NMPA Releases 96th Reference Listed Drugs Catalog, Adding 42 New Generic Specifications
The National Medical Products Administration (NMPA) has just published the 96th edition of its Reference...
CSPC Pharmaceutical Group Submits Anbenitamab for NMPA Approval in HER2‑Positive Gastric Cancer
CSPC Pharmaceutical Group (HKG: 1093) announced today that Anbenitamab Antibody Injection (KN026), co‑developed with Alphamab...
BioNTech and BMS Reveal Promising Interim Results for Pumitamig in ES‑SCLC
BioNTech SE (NASDAQ: BNTX) and Bristol-Myers Squibb (BMS, NYSE: BMY) disclosed interim data from a...
Summit Therapeutics Presents 2025 HARMONi Study Results at World Lung Cancer Conference
Summit Therapeutics (NASDAQ: SMMT) disclosed longer‑term progression‑free survival (PFS) data from its HARMONi trial of...
Guangzhou’s Bio‑Thera Solutions Secures $5.4 Million Milestone from Intas Pharma
Bio-Thera Solutions Ltd. (SHA: 688177) announced today that it has received a $5.4 million milestone payment...
FDA Launches Aggressive Campaign to Curb Misleading Drug Advertisements
The U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration...
MSD scrapes £1 billion UK expansion, shifts life‑science research to the US
US‑based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced the cancellation of...
FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration
Shanghai‑based FibroX Therapeutics announced that its investigational new drug (IND) application for FibroCell, an allogeneic...
NMPA Unveils 30‑Working‑Day Pathway to Accelerate Innovative Drug Trials
The National Medical Products Administration (NMPA) announced a new regulatory framework—Announcement No. 86 of 2025—that promises to...
Genrix Bio Secures NMPA Approval for GR1803 Bispecific Antibody in Systemic Lupus Erythematosus
China‑based Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced that the National Medical Products Administration (NMPA)...
GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58 B
China‑based GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) completed a successful initial public offering (IPO) on the...
Remedium Bio Teams Up With Eli Lilly to Push Gene‑Therapy Frontiers for Diabetes and Obesity
Remedium Bio, Inc. (Remedium) announced a multi‑target R&D partnership with Eli Lilly & Co. (NYSE: LLY) to...
YolTech Raises 300 Million Yuan Series B, Pushing In‑Vivo Gene‑Editing to the Forefront
The AstraZeneca‑CICC Medical Industry Fund announced that it led a Series B financing round for China‑based...
Novartis Secures Tabrecta Approval in China for METex14 NSCLC
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its MET‑receptor tyrosine kinase inhibitor Tabrecta (capmatinib...
China to Add HPV Vaccine to National Immunization Program, Pledges Free Shots for Eligible Girls
At a State Council Information Office press conference, Deputy Director of the National Health Commission...
China’s Drug Evaluation Authority Issues Draft Rules for Class I ATMP Meetings
The Center for Drug Evaluation (CDE), part of China’s National Medical Products Administration (NMPA), published...
China Unveils “Healthcare Foundation Strengthening Plan” to Bring Clinics Within 15‑Minute Reach
The State Council released the Implementation Plan for the Healthcare Foundation Strengthening Project, setting a...
TransThera Sciences Secures China Phase II Trial Approval for Tinengotinib‑Fulvestrant Combination
TransThera Sciences (Nanjing) Inc. (HKG: 2617) announced that the China National Medical Products Administration has...